Repligen Corporation developed a scalable process platform with RoosterBio® using tangential flow depth filtration (TFDF) for clarification and tangential flow filtration (TFF) for concentration and buffer exchange
Published
Signal category
Research & Knowledge
Quote
“In this collaborative study with RoosterBio®, a scalable process platform was developed that replaces traditional harvest centrifugation with tangential flow depth filtration (TFDF®) for clarification and tangential flow filtration (TFF) for concentration and buffer exchange”
— Repligen Corporation team
Company
- Industry
- Biotechnology Research
- Location
- Waltham, US
- Company size
- 1,497 employees
Repligen, a global, bioprocessing-focused life sciences company, provides innovative solutions for the advancement of biotherapeutic manufacturing. Experts in filtration, chromatography systems, process analytics, fluid management, and proteins, Repligen is a trusted partner serving the development and manufacture of a wide range of biologics, including cell and gene therapies, mRNA, monoclonal antibodies (mAbs), antibody–drug conjugates (ADCs), bispecific antibodies, and fusion proteins. Headquartered in Waltham, Massachusetts, USA, Repligen operates across 22 sites, including locations in the United States, Europe, and the Asia-Pacific region.